Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
Connect Biopharma announced positive topline data from its global Phase 2 Seabreeze STAT COPD trial of rademikibart as add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. Rademikibart reduced treatment failure by 81% (p=0.0122), new moderate-to-severe exacerbations by 85% (p=0.030), and hospitalizations or ED visits by 100% (p=0.0137) through Week 4, with a safety profile comparable to placebo. The 159-participant trial also showed a 70 mL greater improvement in FEV(1) at Week 4 that missed statistical significance (p=0.1607).
Key figures
- Drug Name
- rademikibart
- Phase Of Trial
- Phase 2
- Enrolled participants
- 159
- New exacerbation reduction
- 85% (p=0.030)
- Fev1 improvement vs placebo
- 70 mL at Week 4 (p=0.1607)
- Treatment failure reduction
- 81% (p=0.0122)
- Simcere milestones remaining
- $99 million
- Hospitalization ed visit reduction
- 100% (p=0.0137)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.